Brian K. Link, Sergei I. Syrbu, University of Iowa College of Medicine, Iowa City, IA; and Matthew J. Maurer, Grzegorz S. Nowakowski, Stephen M. Ansell, William R. Macon, Susan L. Slager, Carrie A. Thompson, David J. Inwards, Patrick B. Johnston, Joseph P. Colgan, Thomas E. Witzig, Thomas M. Habermann, and James R. Cerhan, Mayo Clinic College of Medicine and Mayo Foundation, Rochester, MN.
J Clin Oncol. 2013 Sep 10;31(26):3272-8. doi: 10.1200/JCO.2012.48.3990. Epub 2013 Jul 29.
This study sought to characterize transformation incidence and outcome for patients with follicular lymphoma (FL) in a prospective observational series begun after diffusion of rituximab use.
Patients with newly diagnosed FL were prospectively enrolled onto the University of Iowa/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource from 2002 to 2009. Patients were actively followed for re-treatment, clinical or pathologic transformation, and death. Risk of transformation was analyzed via time to transformation by using death as a competing risk.
In all, there were 631 patients with newly diagnosed grade 1 to 3a FL who had a median age at enrollment of 60 years. At a median follow-up of 60 months (range, 11 to 110 months), 79 patients had died, and 60 patients developed transformed lymphoma, of which 51 were biopsy proven. The overall transformation rate at 5 years was 10.7%, with an estimated rate of 2% per year. Increased lactate dehydrogenase was associated with increased risk of transformation. Transformation rate at 5 years was highest in patients who were initially observed and lowest in patients who initially received rituximab monotherapy (14.4% v 3.2%; P = .021). Median overall survival following transformation was 50 months and was superior in patients with transformation greater than 18 months after FL diagnosis compared with patients with earlier transformation (5-year overall survival, 66% v 22%; P < .001).
Follicular transformation rates in the immunochemotherapy era are similar to risk of death without transformation and may be lower than reported in older series. Post-transformation prognosis is substantially better than described in older series. Initial management strategies may influence the risk of transformation.
本研究旨在描述滤泡性淋巴瘤(FL)患者在利妥昔单抗广泛应用后的前瞻性观察性系列研究中的转化发生率和结局。
2002 年至 2009 年,新诊断为 FL 的患者前瞻性地入组至爱荷华大学/梅奥诊所专门研究卓越分子流行病学资源项目。对患者进行积极随访,以了解再次治疗、临床或病理转化以及死亡情况。通过转化时间来分析转化风险,以死亡作为竞争风险。
共纳入 631 例新诊断的 1 级至 3a 级 FL 患者,中位年龄为 60 岁。中位随访时间为 60 个月(范围,11 至 110 个月),79 例患者死亡,60 例患者发生转化性淋巴瘤,其中 51 例经活检证实。5 年总转化率为 10.7%,估计每年的转化率为 2%。乳酸脱氢酶升高与转化风险增加相关。初始观察的患者转化率最高(5 年为 14.4%),而初始接受利妥昔单抗单药治疗的患者转化率最低(3.2%;P =.021)。转化后总生存的中位数为 50 个月,FL 诊断后 18 个月以上发生转化的患者比早期转化的患者总生存更好(5 年总生存率,66%比 22%;P <.001)。
在免疫化疗时代,滤泡性转化率与无转化的死亡风险相似,且可能低于旧系列报道的转化率。转化后的预后明显优于旧系列报道。初始治疗策略可能影响转化风险。